1. National Institute for Health and Care Excellence . Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592) [online], 2019. Available: https://www.nice.org.uk/guidance/ta592 [Accessed 6 Jul 2023].
2. National Institute for Health and Care Excellence . Managed access [online], 2023. Available: https://www.nice.org.uk/about/what-we-do/our-programmes/managed-access [Accessed 6 Jul 2023].
3. National Institute for Health and Care Excellence . Cemiplimab for treating cutaneous squamous cell carcinoma (CDF review of TA592) [online], 2022. Available: https://www.nice.org.uk/guidance/ta802/evidence/committee-papers-pdf-11129324797 [Accessed 6 Jul 2023].
4. US National Library of Medicine . Study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma [online], 2023. Available: https://classic.clinicaltrials.gov/ct2/show/NCT02760498 [Accessed 6 Jul 2023].
5. 814P phase II study of Cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3;Migden;Annals of Oncology,2022